'“Even rare vaccination-related harms, both known and unknown, now have a higher chance of outweighing potential benefits in non-high-risk populations,” he wrote in the documents overriding the staff members on the Novavax shot'
https://t.co/0eClZryxuJ
Where's the data on this?
Oversimplifying: MO's got to sufficient power faster than LFP could capture that premium, so LFP lost round one, but emerged as a value play. Amazing. I'll be spicy and say compare A123 of 2008 to QS today. (not really fair b/c A123 had very good commercial cells by '08). 12/n